Skip to main content
Premium Trial:

Request an Annual Quote

Missed Milestone Prompts Galapagos to Slash Value of Inpharmatica Acquisition

NEW YORK (GenomeWeb News) — A missed milestone by Inpharmatica has prompted Galapagos to cut around €7 million from the value of its acquisition of the company, Galapagos said today.
 
The company has already issued 613,000 new shares to former Inpharmatica stockholders, which Galapagos had agreed to acquire last December for as much as €19 million ($25.4 million) in stock.
 
Under that deal, Galapagos was to grant Inpharmatica shareholders as many as 2.2 million shares priced at €8.82 apiece based on certain milestones, cash on hand, and worth as a business. Galapagos issued 623,000 shares at the time of the agreement.
 
Today, Galapagos said that Inpharmatica failed to meet one of these milestones, resulting in a loss of the 815,000 shares.
 
Galapagos said it will issue a maximum of 113,000 more shares in May to complete the acquisition, bringing the total exchange to around €12 million.
 
The company also separately issued a total of 14,800 shares as part of warrants to Galapagos employees and its Dutch affiliate.

Filed under

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.